Revolutionizing Lupus Care with Advanced Predictive Blood Testing

Apr 22, 2024 | News, Lupus 2022, Products

AMPEL Biosolutions logo



AMPEL BioSolutions introduces LuGENE®, a cutting-edge blood test poised to revolutionize the management of systematic lupus erythematosus (SLE). LuGENE® leverages predictive artificial intelligence (AI) to detect genetic biomarkers indicative of inflammation-driven SLE flares, offering clinicians valuable insights for tailored treatment strategies. With SLE’s complex nature and diverse manifestations across individuals, LuGENE® provides a crucial tool for predicting and preempting flare-ups, ultimately enhancing patient care and outcomes. Now available at select study sites across the United States, LuGENE® represents a significant advancement in lupus management and research. Stay tuned to the Lupus Foundation of America for updates on LuGENE® and other developments in lupus research and treatment.

Pin It on Pinterest